Alnylam Pharmaceuticals Inc (ALNY)vsEnliven Therapeutics Inc. (ELVN)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
ELVN
Enliven Therapeutics Inc.
$35.53
+14.06%
HEALTHCARE · Cap: $1.86B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
ELVN
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for ELVN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ELVN
The strongest argument for ELVN centers on Altman Z-Score.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : ELVN
The primary concerns for ELVN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ELVN is a value play — different risk/reward profiles.
ELVN carries more volatility with a beta of 1.06 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 28/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Enliven Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer treatment and addressing other serious diseases through its proprietary therapeutic platforms. The firm possesses a promising pipeline of cutting-edge drug candidates, developed using advanced biopharmaceutical technologies, with the goal of enhancing patient outcomes and overall quality of life. With a steadfast commitment to scientific excellence and the pursuit of solutions for significant unmet medical needs in oncology, Enliven is strategically positioned to generate shareholder value while contributing positively to the healthcare landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?